PRECLINICAL RESEARCH AND SYSTEMATIC PRODUCTION OF INNOVATIVE MEDICAL RADIO-ISOTOPES AT ISOL@MYRRHA

Research output: Contribution to journalArticle

Documents & links

Abstract

The wide spectrum of radioactive ion beams that can be produced and the fact that they can be obtained essentially carrier free, makes ISOL facilities a unique tool for preclinical studies of innovative radioisotopes. Such kind of studies is being carried out already at existing facilities, like at CERN-ISOLDE. An illustrative example is the production of 149Tb, for which promising results were observed in a dedicated alpha-therapy study on Severe Combined Immuno-Deficient (SCID) mice. However, the demand for beam time at ISOL facilities is extra-ordinary, resulting in typical beam-time periods for an experiment of several days up to two weeks at maximum. ISOL@MYRRHA, on the other hand, will be unique in the sense that programs in need of extended beam times will be prioritized. In combination with the intense RIBs, this might open the possibility to produce in a systematic manner innovative carrier-free radioisotopes like, for example, the alpha-emitter 149Tb and the PET isotope 151Tb. The latter would then form a so-called "matched pair" with 149Tb, but also with the beta(-)-emitter 161Tb. In this paper, we present the opportunities for innovative medical radioisotopes at ISOL@MYRRHA

Details

Original languageEnglish
Pages (from-to)111-111
JournalRadiotherapy & Oncology Journal
Volume102
Issue number1
DOIs
Publication statusPublished - Mar 2012
EventICTR-PHE 2012 Conference - Geneva, Switzerland
Duration: 27 Feb 20122 Mar 2012

Keywords

  • medical radioisotopes, ISOL@MYRRHA, radioactive ion beams 149Tb

ID: 290539